---
title: "Traws Pharma Provides Regulatory Update on Influenza Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289644312.md"
description: "Newtown-based Traws Pharma, Inc. revealed that the anticipated Phase 2a human influenza challenge study involving tivoxavir marboxil (TXM) has been postponed. This decision follows a discouraging evaluation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Traws Pharma, Inc., listed as TRAW on NASDAQ, specializes in pioneering therapies for global viral threats. The company had high hopes for TXM, but setbacks have caused a delay in the clinical trial process. The MHRA's review results have led to a disruption in the development timeline for this crucial study."
datetime: "2026-06-12T21:31:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289644312.md)
  - [en](https://longbridge.com/en/news/289644312.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289644312.md)
generator: "portal-rs"
---

# Traws Pharma Provides Regulatory Update on Influenza Program

Newtown-based Traws Pharma, Inc. revealed that the anticipated Phase 2a human influenza challenge study involving tivoxavir marboxil (TXM) has been postponed. This decision follows a discouraging evaluation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Traws Pharma, Inc., listed as TRAW on NASDAQ, specializes in pioneering therapies for global viral threats. The company had high hopes for TXM, but setbacks have caused a delay in the clinical trial process. The MHRA's review results have led to a disruption in the development timeline for this crucial study.

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)

## Related News & Research

- [NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects](https://longbridge.com/en/news/298966653.md)
- [SRRK: ISEMBYLD receives FDA approval as the first muscle-targeted SMA therapy, launching in the U.S](https://longbridge.com/en/news/298774302.md)
- [VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options](https://longbridge.com/en/news/298956231.md)
- [Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy](https://longbridge.com/en/news/298778598.md)
- [Armata says FDA grants Breakthrough Therapy designation for AP-SA02 in complicated Staph aureus bacteremia](https://longbridge.com/en/news/298907025.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**